252 related articles for article (PubMed ID: 11872398)
1. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.
Coombs GH; Goldberg DE; Klemba M; Berry C; Kay J; Mottram JC
Trends Parasitol; 2001 Nov; 17(11):532-7. PubMed ID: 11872398
[TBL] [Abstract][Full Text] [Related]
2. Targeting polyamines of parasitic protozoa in chemotherapy.
Müller S; Coombs GH; Walter RD
Trends Parasitol; 2001 May; 17(5):242-9. PubMed ID: 11323309
[TBL] [Abstract][Full Text] [Related]
3. Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X.
Li F; Bounkeua V; Pettersen K; Vinetz JM
Malar J; 2016 Feb; 15():111. PubMed ID: 26911483
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
[TBL] [Abstract][Full Text] [Related]
5. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine.
Banerjee R; Liu J; Beatty W; Pelosof L; Klemba M; Goldberg DE
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):990-5. PubMed ID: 11782538
[TBL] [Abstract][Full Text] [Related]
6. The aspartic proteinase from the rodent parasite Plasmodium berghei as a potential model for plasmepsins from the human malaria parasite, Plasmodium falciparum.
Humphreys MJ; Moon RP; Klinder A; Fowler SD; Rupp K; Bur D; Ridley RG; Berry C
FEBS Lett; 1999 Dec; 463(1-2):43-8. PubMed ID: 10601635
[TBL] [Abstract][Full Text] [Related]
7. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
Savarino A; Cauda R; Cassone A
J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
[No Abstract] [Full Text] [Related]
8. Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets.
Qidwai T
Curr Drug Targets; 2015; 16(10):1133-41. PubMed ID: 25738296
[TBL] [Abstract][Full Text] [Related]
9. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion.
Nasamu AS; Glushakova S; Russo I; Vaupel B; Oksman A; Kim AS; Fremont DH; Tolia N; Beck JR; Meyers MJ; Niles JC; Zimmerberg J; Goldberg DE
Science; 2017 Oct; 358(6362):518-522. PubMed ID: 29074774
[TBL] [Abstract][Full Text] [Related]
10. Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole.
Luker KE; Francis SE; Gluzman IY; Goldberg DE
Mol Biochem Parasitol; 1996 Jul; 79(1):71-8. PubMed ID: 8844673
[TBL] [Abstract][Full Text] [Related]
11. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation.
Hammarton TC; Mottram JC; Doerig C
Prog Cell Cycle Res; 2003; 5():91-101. PubMed ID: 14593704
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance and ABC transporters in parasitic protozoa.
Ouellette M; Légaré D; Papadopoulou B
J Mol Microbiol Biotechnol; 2001 Apr; 3(2):201-6. PubMed ID: 11321574
[TBL] [Abstract][Full Text] [Related]
13. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
Bobrovs R; Jaudzems K; Jirgensons A
J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
[TBL] [Abstract][Full Text] [Related]
14. Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum.
Klemba M; Goldberg DE
Mol Biochem Parasitol; 2005 Oct; 143(2):183-91. PubMed ID: 16024107
[TBL] [Abstract][Full Text] [Related]
15. New mechanisms of drug resistance in parasitic protozoa.
Borst P; Ouellette M
Annu Rev Microbiol; 1995; 49():427-60. PubMed ID: 8561467
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerases as targets for antiprotozoal therapy.
Bakshi RP; Shapiro TA
Mini Rev Med Chem; 2003 Sep; 3(6):597-608. PubMed ID: 12871162
[TBL] [Abstract][Full Text] [Related]
17. Aspartic proteases of Plasmodium vivax are highly conserved in wild isolates.
Na BK; Lee EG; Lee HW; Cho SH; Bae YA; Kong Y; Lee JK; Kim TS
Korean J Parasitol; 2004 Jun; 42(2):61-6. PubMed ID: 15181345
[TBL] [Abstract][Full Text] [Related]
18. Naturally-occurring and recombinant forms of the aspartic proteinases plasmepsins I and II from the human malaria parasite Plasmodium falciparum.
Tyas L; Gluzman I; Moon RP; Rupp K; Westling J; Ridley RG; Kay J; Goldberg DE; Berry C
FEBS Lett; 1999 Jul; 454(3):210-4. PubMed ID: 10431809
[TBL] [Abstract][Full Text] [Related]
19. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
[TBL] [Abstract][Full Text] [Related]
20. Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets.
Moon RP; Bur D; Loetscher H; D'Arcy A; Tyas L; Oefner C; Grueninger-Leitch F; Mona D; Rupp K; Dorn A; Matile H; Certa U; Berry C; Kay J; Ridley RG
Adv Exp Med Biol; 1998; 436():397-406. PubMed ID: 9561248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
